Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.

Journal of translational medicine - 27 Oct 2025

Zhang Kexin, Ge Yi, Xu Yishi, Zhang Chuhan, Wang Liping

Abstract excerpt

BACKGROUND: EGFR exon 20 insertion mutations (ex20ins) represent the third most common epidermal growth factor receptor (EGFR) mutation subtype in non-small cell lung cancer (NSCLC). Conventional EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy demonstrate suboptimal efficacy in patients harboring EGFR ex20ins mutations. Furmonertinib, a highly selective EGFR-TKI with enhanced blood-brain barrier...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41146268
DOI: 10.1186/s12967-025-07114-w
PMCID: PMC12560556

Genes

EGFR
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.PMID 41146268Read ↗

Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome.Semantic proximity Read ↗

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.Semantic proximity Read ↗

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertionsSemantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancerSemantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC.Semantic proximity Read ↗

Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.Semantic proximity Read ↗

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenSemantic proximity Read ↗

Mobocertinib: Mechanism of action, clinical, and translational science.Semantic proximity Read ↗

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.Semantic proximity Read ↗

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.